stockrow
Monday 9 November 2026
Export ABEO’s income statement to Excel — free account
Abeona Therapeutics Inc.
ABEOAbeona Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.8 million, up 66.3% from fiscal 2023.
- Revenue
- +225.1%
- EPS
- −116.9%
- Free cash flow
- +17.1%
- Total debt
- −23.4%
Quarter to June 2026, against a year earlier
4.17
0.26
+6.65%
Follow ABEO
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 1 | 1 | 3 | — | 10 | 3 | 1 | 4 | — | 6 | 26 | +23.2% | 53 | 116 | 189 | +218.8% | |
| Gross margin, % | 100.00 | 100.00 | 100.00 | 0.00 | 100.00 | 100.00 | 68.18 | 54.14 | — | 73.68 | 66.03 | (26.3) pt | ||||||
| EBT | (22) | (27) | (57) | (76) | (84) | (85) | (40) | (54) | (64) | 71 | (78) | n/m | ||||||
| EBT margin, % | (2,460.40) | (3,263.92) | (1,890.29) | 0.00 | (842.34) | (2,831.20) | (2,807.36) | (1,548.23) | 0.00 | 1,224.79 | (302.07) | +3,685.2 pt | ||||||
| Net income | (22) | (27) | (57) | (76) | (84) | (85) | (40) | (54) | (64) | 71 | (63) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.65 | 0.50 | 1.58 | 0.00 | 2.70 | 0.76 | 0.18 | 0.16 | 0.00 | 0.11 | 0.45 | (17.9%) | |||||
| Earnings | (16.00) | (16.50) | (29.75) | (37.75) | (22.75) | (21.50) | (5.53) | (2.53) | (1.55) | 1.34 | (1.17) | n/m | ||||||
| Cash flow | (9.52) | (13.60) | (20.57) | (31.19) | (9.45) | (16.67) | (5.53) | (1.73) | (1.36) | (1.44) | (1.34) | (18.9%) | ||||||
| Capex | (0.38) | (0.52) | (4.86) | (3.13) | (0.36) | (1.05) | 0.20 | (0.01) | (0.06) | (0.15) | (0.09) | (9.8%) | ||||||
| Free cash flow | (9.90) | (14.12) | (25.43) | (34.32) | (9.81) | (17.73) | (5.33) | (1.74) | (1.42) | (1.59) | (1.43) | (18.4%) | ||||||
| Book value | 72.48 | 102.13 | 70.51 | 88.59 | 27.67 | 10.76 | 3.40 | 0.69 | 1.07 | 3.01 | 2.24 | (29.8%) | ||||||
| Shares, m | 1 | 2 | 2 | 2 | 4 | 4 | 8 | 21 | 41 | 53 | 55 | +50.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | — | 4.02 | 0.00 | 0.5 | |||||
| P/S | 192.24 | 855.63 | 113.19 | — | 11.93 | 2.46 | 5.09 | 29.04 | — | 29.73 | 9.18 | 154.9 | ||||||
| P/B | 1.72 | 4.21 | 2.53 | — | 1.42 | 0.78 | 0.84 | 9.62 | — | 1.75 | 1.86 | 2.9 | ||||||
| EV/Sales | 118.96 | 695.84 | 86.18 | — | 4.42 | (0.62) | (5.07) | 19.50 | — | 11.47 | 4.09 | 116.3 | ||||||
| EV/FCF | (7.81) | (24.77) | (5.34) | — | (1.48) | 0.12 | 0.53 | (2.58) | — | (1.28) | (1.30) | (5.3) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (13) | (23) | (39) | (63) | (35) | (66) | (43) | (37) | (56) | (76) | (76) | +21.7% | |||||
| Capex | (1) | (1) | (9) | (6) | (1) | (4) | 2 | 0 | (2) | (8) | (5) | +35.5% | ||||||
| Free cash flow | (14) | (24) | (48) | (69) | (36) | (70) | (42) | (37) | (58) | (84) | (82) | +22.5% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 61 | 135 | 68 | 94 | 56 | 40 | 45 | 42 | 84 | 175 | 140 | +12.4% | |||||
| Net debt | (69) | (138) | (85) | (121) | (92) | (42) | (45) | (53) | (79) | (171) | (132) | +10.6% | ||||||
| Shareholders’ equity | 99 | 170 | 134 | 178 | 103 | 42 | 27 | 15 | 44 | 159 | 128 | +5.4% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (22.89) | (18.85) | (32.09) | (38.35) | (44.98) | (73.61) | (60.47) | (84.53) | (73.71) | 43.34 | (29.54) | +66.2 pt | |||||
| ROIC | (49.83) | (53.78) | (74.07) | (84.35) | (463.12) | (6,756.62) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | +49.8 pt | ||||||
| ROE | (26.22) | (20.30) | (37.27) | (48.82) | (59.96) | (117.22) | (125.79) | (260.60) | (216.57) | 70.05 | (43.13) | +96.3 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 19 | 42 | 83 | 88 | 76 | 90 | 57 | 84 | 136 | 226 | — | +31.7% | |||||
| Revenue/emp, $m | 0.05 | 0.02 | 0.04 | 0.00 | 0.13 | 0.03 | 0.02 | 0.04 | 0.00 | 0.03 | — | (6.4%) | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
Abeona Therapeutics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CABA Cabaletta Bio, Inc. | $280.4M | — (loss-making) | — | — | n/m | −35.72% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| EVMN Evommune Inc. | $241.3M | — (loss-making) | — (loss-making) | — | n/m | +21.78% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ABEO Abeona Therapeutics Inc. | $238.5M | — (loss-making) | — (loss-making) | +225.14% (above 0%: growing) | n/m | +17.11% (above 0%: growing) | 63.30% | (119.97%) | |
| IMRX Immuneering Corporation | $238.3M | — (loss-making) | — (loss-making) | −99.74% (below 0%: shrinking) | n/m | −40.19% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| VNDA Vanda Pharmaceuticals Inc. | $231.0M | — (loss-making) | — (loss-making) | +24.10% (above 0%: growing) | n/m | +9.57% (above 0%: growing) | 94.05% | (33.69%) | Compare |
| ACIU AC Immune | $227.0M | — (loss-making) | — (loss-making) | +152.31% (above 0%: growing) | n/m | +4.66% (above 0%: growing) | 100.00% | (302.13%) | Compare |
| FATE Fate Therapeutics, Inc. | $223.1M | — (loss-making) | — (loss-making) | +9.18% (above 0%: growing) | n/m | +8.96% (above 0%: growing) | 100.00% | (1,495.39%) | Compare |
| GLSI Greenwich LifeSciences, Inc. | $222.7M | — (loss-making) | — | — | n/m | +13.14% (above 0%: growing) | 0.00% | 0.00% | Compare |
| KRRO Korro Bio, Inc. | $202.5M | — (loss-making) | — (loss-making) | −86.28% (below 0%: shrinking) | n/m | +12.07% (above 0%: growing) | 100.00% | 0.00% | Compare |
| Median of peers | $229.0M | — | — | +9.18% | — | +9.27% | 97.03% | 0.00% |
Pay and ownership Proxy statement filed 27 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 3.99m | 4.04m | 171.10 |
| 2024 | 3.51m | 3.99m | 180.84 |
| 2023 | 2.85m | 3.46m | 162.66 |
Ownership
Directors and executive officers, together
7.10%
Nantahala Capital Management, LLC
9.10%
Funicular Funds
5.30%
Daniel Kaufman
5.20%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement